Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: sjemmeri who wrote (14467)	12/3/2004 10:22:29 AM
From: scaram(o)uche	Respond to of 52153

Steve: Watched them since they were tiny, and can only say that I admire the job that management has done. finance.yahoo.com Bubble returns were sorta nice. Otherwise, it hasn't turned out to be the prototype biotech investment. rkrw used to follow them. Not much help. Rick

To: sjemmeri who wrote (14467)	12/3/2004 10:24:39 AM
From: rkrw	Respond to of 52153

I think novn is a pretty safe investment at these prices, albeit unexciting. Got hurt with this PG news as they're working on a next gen intrinsa patch for pg. Also concerns their duragesic generic approval may come a bit after mylan's hits the market. So have taken a couple of hits over the past month. novn patches for hrt have been held up well post whi as patches are perceived as safer, less systemic. hrt biz with novartis provides a nice floor.